HOME >> MEDICINE >> NEWS
GroPep to pursue promising asthma drug following preclinical study results

Adelaide biotechnology company GroPep has completed preclinical efficacy studies of its T-cell peptide drug candidate, in models of psoriasis and asthma.

GroPep will undertake a market feasibility assessment for the use of the drug in asthma but will cease development for psoriasis.

Current annual sales of asthma drugs in the United States alone exceed US$4.0 billion and are growing at over 10%. GroPep has international patent coverage for the T-cell peptide technology.

Listed biopharmaceutical company GroPep Limited (ASX: GRO) announced today that it had completed testing of its T-cell peptide drug candidate in preclinical models of asthma and psoriasis.

The results showed that the drug was highly effective in treating asthma but had little effect in a model of psoriasis when applied to the skin, even in an efficient formulation. As a result, the Company will direct its resources in the highly profitable field of immune-based diseases towards asthma, and will cease development for psoriasis.

As previously reported by the Company, initial research conducted at the Royal North Shore Hospital, Sydney by Professor Manolios showed the drug has potential in a range of autoimmune diseases.

Exclusive, worldwide rights to key patents covering the drug were obtained by GroPep in 2002, through a licence from the Northern Sydney and Central Coast Area Health Service.

In May 2005, GroPep filed a new International Patent Application on the use of the drug for the treatment of asthma, based on the work of Professor Enk at the University of Mainz, Germany Asthma affects more than 15 million people in the US alone and 100 million people worldwide. The market is increasing because of an ageing population and the contribution of pollution, smoking and airborne allergens. Current sales of asthma drugs in the United States alone exceed US$4.0 billion and are growing annually at over 10%.

GroPep's Chief Operat
'"/>

Contact: Tony Mitchell
61-883-547-700
Research Australia
14-Dec-2005


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep starts Phase 1 infertility trial
3. GroPep completes final milestone of the path malaria vaccine initiative
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Half of active children pursue non-traditional physical activities
7. ICSU pursues new initiative that challenges science to do more to prevent natural disasters
8. Study shows Philip Morris pursued tobacco regulation to enhance its image
9. Study: Directly observed HIV therapy for children is promising
10. Childhood obesity intervention shows promising results
11. Animal study identifies promising new target for brain tumor therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2019)... ... April 17, 2019 , ... Kadan Homecare, an award-winning ... announced today that it has received both the 2019 Best of Home Care® – ... are granted only to the top-ranking home care providers, based on client and caregiver ...
(Date:4/17/2019)... HAVEN, Conn. (PRWEB) , ... April 17, 2019 ... ... community for IBS sufferers, announced a new initiative this April to designate April ... and to show strong support for research & healthcare professionals in their pursuit ...
(Date:4/17/2019)... ... April 17, 2019 , ... Fertility Centers of Illinois ... an effort to unite millions of Americans aiming to remove the stigmas and ... initiative, Fertility Centers of Illinois is offering seven free physician-led webinars and free ...
(Date:4/17/2019)... ... April 17, 2019 , ... An upcoming episode of Innovations ... episode is scheduled to air 3Q 2019 on FOX Business. Check your local ... Biomedical Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
(Date:4/17/2019)... ... 17, 2019 , ... Signaled.online is a notification service designed for personal use. ... the web resources and reminder. , The alarm can be useful while traveling abroad, ... you haven’t logged in to the website for several days (this period is set ...
Breaking Medicine News(10 mins):
(Date:4/17/2019)... ... April 17, 2019 , ... ... therapies for diseases involving mitochondrial dysfunction, announced yesterday at the 2019 Muscular ... TAZPOWER and open-label extension (OLE) clinical trial evaluating efficacy of elamipretide, an ...
(Date:4/17/2019)... (PRWEB) , ... April 17, 2019 , ... ... Inc., (NYSE:VTR) and one of the nation’s largest owners and operators of medical ... of 11 healthcare industry experts during the Building Owners and Managers Association (BOMA) ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics’ ... alike. , Through years of experience helping sponsors manage complex oncology trials, ...
Breaking Medicine Technology:
Cached News: